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Introduction: Endocrine therapies target oestrogenic stimulation of breast cancer (BC) growth, but resistance
remains problematic. Our aims in this study were (1) to identify genes most strongly associated with resistance to
endocrine therapy by intersecting global gene transcription data from patients treated presurgically with the
aromatase inhibitor anastrazole with those from MCF7 cells adapted to long-term oestrogen deprivation (LTED) (2)
to assess the clinical value of selected genes in public clinical data sets and (3) to determine the impact of targeting
these genes with novel agents.
Methods: Gene expression and Ki67 data were available from 69 postmenopausal women with oestrogen
receptor–positive (ER+) early BC, at baseline and 2 weeks after anastrazole treatment, and from cell lines adapted
to LTED. The functional consequences of target genes on proliferation, ER-mediated transcription and downstream
cell signalling were assessed.
Results: By intersecting genes predictive of a poor change in Ki67 with those upregulated in LTED cells, we
identified 32 genes strongly correlated with poor antiproliferative response that were associated with inflammation
and/or immunity. In a panel of LTED cell lines, C-X-C chemokine receptor type 7 (CXCR7) and CXCR4 were upregulated
compared to their wild types (wt), and CXCR7, but not CXCR4, was associated with reduced relapse-free survival in
patients with ER+ BC. The CXCR4 small interfering RNA variant (siCXCR4) had no specific effect on the proliferation of
wt-SUM44, wt-MCF7 and their LTED derivatives. In contrast, siCXCR7, as well as CCX733, a CXCR7 antagonist, specifically
suppressed the proliferation of MCF7-LTED cells. siCXCR7 suppressed proteins associated with G1/S transition and
inhibited ER transactivation in MCF7-LTED, but not wt-MCF7, by impeding association between ER and proline-,
glutamic acid– and leucine-rich protein 1, an ER coactivator.
Conclusions: These data highlight CXCR7 as a potential therapeutic target warranting clinical investigation in
endocrine-resistant BC.Introduction
Approximately 80% of the breast cancers (BCs) express
oestrogen receptor α (ER) at the time of primary diagnosis
and depend on oestrogen for their growth and progres-
sion. Several endocrine therapies have been developed
clinically to target this pathway, including aromatase in-
hibitors (AIs), which block the conversion of androgens to
oestrogens; selective ER modulators such as tamoxifen,* Correspondence: lesley-ann.martin@icr.ac.uk
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(ICI 182,780), which binds to ER and targets it for degrad-
ation. Despite the efficacy of these agents, many patients
eventually relapse with either intrinsic or acquired resist-
ance and, in the majority of cases, continue to express ER.
The elucidation of the molecular pathways governing
resistance is crucial for the identification of biomarkers
and novel therapeutic strategies. To answer these ques-
tions, we, like others, have developed in vitro models
mimicking relapse on AIs. We have previously demon-
strated that crosstalk between ER and type I and type II
growth factor receptor tyrosine kinases, most notablytd. This is an Open Access article distributed under the terms of the Creative
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mones leading to ligand independent activation of the
ER or can provide a hypersensitive field in which the ER
can respond to very low levels of oestrogen [1-8]. Al-
though there is some clinical evidence to support these
preclinical findings, only 10% of ER+ tumours coexpress
ERBB2, and ERBB2 is rarely overexpressed with acquisi-
tion of resistance [9]. This suggests that alternative under-
lying molecular events remain to be identified.
To address this question, we took a three-way strategy.
(1) We examined the intersection of (a) global gene tran-
scription data from ER+ breast tumours of patients treated
with neoadjuvant anastrazole with (b) data from MCF7
cells adapted to long-term oestrogen deprivation (LTED).
(2) We assessed the clinical value of selected genes in
public clinical data sets. (3) We determine the function
and utility of these proteins as novel therapeutic targets.
In particular, we found genes associated with inflamma-
tion and immunity, such as C-X-C chemokine receptors
(CXCRs), as potential biomarkers of poor response. CXCRs
belong to the family of seven transmembrane receptors
responsible for the initiation of a cascade of signal trans-
duction events (Figure 1). Previous studies have shown that
CXCRs are involved in the development of several types of
cancer by promoting cell growth, metastasis and resistance
to chemotherapy [10].
In the present study, we provide evidence for the role
of CXCR7 in endocrine resistance. Clinical data demon-
strate that CXCR7 is associated with poor relapse-freeFigure 1 Schematic representation of signalling pathways of
C-X-C chemokine receptors CXCR4 and CXCR7. MAPK, Mitogen-
activated protein kinase; PKC, Protein kinase C.survival (RFS) in BC patients. Additionally, in vitro models
of endocrine resistance provide evidence of novel crosstalk
between ER, PELP/MNAR (proline-, glutamic acid– and
leucine-rich protein 1/modulator of nongenomic activity
of ER) and CXCR7, highlighting this axis as a potential
therapeutic target in endocrine-resistant BC.
Methods
Cell culture
Human BC cell lines were obtained from the American
Type Culture Collection (Manassas, VA, USA). MCF7,
HCC1428, ZR75.1, T47D and SUM44 (ER+) cell lines
were cultured in phenol red–free RPMI 1640 medium
supplemented with 10% dextran-coated charcoal (DCC)–
stripped serum and 1 nM oestradiol (E2). LTED deriva-
tives modelling resistance to an AI were cultured in the
absence of E2. ER−MDA-MB-231 cells were cultured in
RPMI 1640 medium containing 10% foetal bovine serum.
Gene expression microarray analysis
Cell lines
Global gene expression data were available from MCF7
cells adapted to LTED [11] (ArrayExpress accession num-
ber E-MTAB-922). Differential gene expression analyses
between both cell models were performed in a pairwise
fashion using BRB-ArrayTools (developed by Dr. Richard
Simon and the BRB-ArrayTools Development Team).
Breast tumours
Paired core-cut tumour biopsies were obtained from 69
postmenopausal women with stages I to IIIB ER+ early
BC. The biopsies were obtained at baseline and after a
2-week course of single-agent neoadjuvant anastrozole
therapy. RNA extracted from biopsies was hybridised
onto HumanWG-6 v2 Expression BeadChips (Illumina,
San Diego, CA, USA). Global gene expression and Ki67
data were available [12]. Spearman’s rank correlation
coefficient was used to identify the genes that were pre-
dictive of good or poor change in Ki67 between baseline
gene expression and Ki67 protein level change. Data were
extracted, transformed, normalised and filtered using the
same methods as those used for the cell lines [11]. The
detailed methodology used for this work, as well as the
patient demographics, are published elsewhere [12]. This
study received approval from an institutional review
boards at each site and was conducted in accordance with
the 1964 Declaration of Helsinki and International
Conference on Harmonization/Good Clinical Practice
guidelines. Written informed consent was obtained from
each patient before participation.
Analysis of clinical public data sets
Survival analysis was carried out using the publicly avail-
able online tool KM plotter [13]. Prognostic values for
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untreated ER+ patients (determined by immunohistoche-
mistry) with follow-up of 12 years. The highest quartile of
the gene expression was used to dichotomise the patient
population into high and low groups. The same parame-
ters were used to determine the on-treatment effect of
tamoxifen in 840 patients with follow-up data at 5 and
12 years. A significant impact on RFS was assumed to be
present if the log-rank P-value was <0.05.
Proliferation assays
Wild-type MCF7 (wt-MCF7) and MCF7-LTED cells
were seeded into 10% DCC medium in 96-well plates at
3 × 103 and 1.5 × 103 cells/well, respectively. wt-SUM44
and SUM44-LTED cells were seeded at a density of
2 × 103 cells/well. Twenty-four hours later, monolayers
were transfected with 50 nM of ON-TARGETplus siRNA
(Dharmacon/GE Healthcare Life Sciences, Lafayette,
CO, USA) against nontargeting pool (sicontrol), human
CXCR4 pool, human CXCR7 pool or deconvoluted small
interfering RNAs (siRNAs) using Lipofectamine RNAi-
Max reagent (Invitrogen, Carlsbad, CA, USA) for 24 hours.
Cells were subsequently treated with vehicle (either DCC
alone or DCC with 1 nM E2) for 4 days. For experiments
involving inhibitors, cells were cultured in DCC for 3 days
and seeded as specified above. Twenty-four hours later,
cells were treated with the CXCR7 antagonist CCX733 or
with CCX704, an analogue with no binding affinity to
CXCR7 [14] (ChemoCentryx, Mountain View, CA, USA).
Drugs were diluted in dimethyl sulphoxide, and mono-
layers were treated at concentrations between 0 and 1,000
nM. Effects at concentrations above 5,000 nM were con-
sidered nonspecific [15]. Cells were treated for 6 days,
with a treatment change on day 3. Cell viability was deter-
mined using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega, Madison, WI, USA). Each experiment
was performed at least three times. A control 24-well plate
was harvested 48 hours after siRNA transfection to
verify the knockdown of CXCR7 by quantitative RT-PCR
(qRT-PCR).
Fluorescence-activated cell sorting analysis
Cell surface expression of CXCR7 was determined using
fluorescence-activated cell sorting (FACS). MDA-MB-231,
wt-MCF7 and MCF7-LTED cells were cultured under their
respective basal conditions. Cells were collected and incu-
bated with mouse monoclonal CXCR7 antibody (11G8;
a gift from Mark Penfold, ChemoCentryx) or mouse im-
munoglobulin G1 (IgG1; Dako, Carpinteria, CA, USA)
for 30 minutes at 4°C. After a series of washes, cells
were incubated with Alexa Fluor 488 goat anti-mouse
IgG antibody and counterstained with 4′,6-diamidino-
2-phenylindole (DAPI). CXCR7 content was determined
in a BD LSR II flow cytometer using BD FACSDiva software(BD Biosciences, San Jose, CA, USA), and the data were
analysed using the FlowJo software program (FlowJo,
Ashland, OR, USA).
Apoptosis assay
Apoptosis was measured using the Cell Death Detection
ELISAPLUS kit (Roche Life Science, Indianapolis, IN, USA)
according to the manufacturer’s instructions.
Cell cycle analysis
Cells were transfected with sicontrol or siCXCR7 as
described above and subsequently treated for 48 hours
with DCC containing vehicle or 1 nM E2. Cells were
collected and fixed overnight with 90% ethanol, then
stained with bromodeoxyuridine and propidium iodide
(Sigma-Aldrich, St Louis, MO, USA) and analysed as
previously described [16].
Transcriptional assays
Cells were plated and transfected with sicontrol or
siCXCR7 and were treated the following day with oestrogen
response element (ERE)–linked luciferase reporter and
β-galactosidase constructs [11]. The activity of luciferase
(Promega) and β-galactosidase (GalactoStar; Applied
Biosystems, Foster City, CA, USA) was measured using a
luminometer. Each experiment was performed three
times. A control plate was used to verify the knockdown
of CXCR7 at the RNA level.
Real-time quantitative PCR
mRNA was extracted using the RNeasy Mini Kit (QIAGEN,
Valencia, CA, USA), and quantification was performed
using Agilent 2100 Bioanalyzer Expert Software (version
B.02.03) with RNA Nano LabChip kits (Agilent Technolo-
gies, Wokingham, UK). Total RNA was reverse-transcribed
using SuperScript III reverse transcriptase (Invitrogen) and
random primers in accordance with the manufacturer’s in-
structions. cDNA was subjected to qRT-PCR experiments
in triplicate. TaqMan gene expression assays (Applied
Biosystems) were performed to quantify CXCR4
(Hs00237052_m1), CXCR7 (Hs00604567_m1), CXCL11
(Hs00171138_m1), CXCL12 (Hs00171022_m1), TFF1
(Hs00907239_m1) and BCL2 (Hs00608023_m1), together
with FKBP15 (Hs00391480_m1) as a housekeeping gene,
to normalise the data. To measure gene expression, we
used the ΔΔCt method for relative quantification or a
standard curve generated from serial dilutions of refer-
ence cDNA from pooled BC cell lines for absolute
quantification.
Immunohistochemistry
Formalin-fixed, paraffin-embedded cells were stained for
CXCR7 (1:2,000 dilution with antibody 11G8 for detec-
tion) using the EnVision FLEX +High pH kit according to
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was conducted using the Autostainer Immunostaining
System (Dako).
Western blot analysis
Whole-cell extracts were generated as described previ-
ously [5]. Equal amounts of protein were resolved by
SDS-PAGE and transferred to nitrocellulose membranes
(Whatman/GE Healthcare Life Sciences, Maidstone, UK).
Antigen–antibody interactions were detected with Amer-
sham ECL detection reagents (Amersham/GE Healthcare
Life Sciences, Little Chalfont, UK). The following primary
antibodies were used: phosphorylated AKT (pAKT), cyclin
D1, phosphorylated Rb807, CDK4, CDK7, Bcl-2, phos-
phorylated p38, phosphorylated protein kinase A (pPKA),
phosphorylated stress-activated protein kinase c-Jun
N-terminal kinase (SAPK/pJNK) and phosphorylated
ER serine 118 and serine 167 (all from Cell Signaling
Technology, Danvers, MA, USA); total ER and poly
(ADP-ribose) polymerase (PARP) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA); phosphorylated extra-
cellular signal-regulated kinases 1 and 2 (pERK1/2),
α-tubulin and β-actin (Sigma-Aldrich); BUB1 and pCDK7
(Abcam, Cambridge, UK); cyclin B1 (Thermo Scientific,
Rockford, IL, USA); and β-arrestin 1 and β-arrestin 2 (gift
from Jeffrey Benovic). Secondary antibodies (anti-mouse
and anti-rabbit horseradish peroxidase) were obtained
from Dako.
Immunofluorescence and confocal studies
Cells were seeded onto glass coverslips in 10% DCC
media. Nonsense or siRNA against human CXCR7 was
transfected at 50 nM using Lipofectamine RNAiMax.
After 24 hours, cells were treated with DCC media for
48 hours. Monolayers were fixed in 4% paraformalde-
hyde in phosphate-buffered saline (PBS) for 15 minutes,
then permeabilised with 0.5% Triton X-100 in PBS for
10 minutes. Cells were subsequently incubated with the
anti-CXCR7 antibody 11G8 for 2 hours. Coverslips were
incubated in Alexa Fluor 488–labelled secondary anti-
body (1:1,000; Molecular Probes, Eugene, OR, USA) for
1 hour. Nuclei were counterstained with DAPI (1:10,000;
Invitrogen). Coverslips were mounted onto glass slides
using VECTASHIELD Mounting Medium (Vector La-
boratories, Peterborough, UK). Images were collected
sequentially in the two channels on an LSM 710
confocal microscope (Zeiss, Oberkochen, Germany).
Immunoprecipitation
Cell lysates were precleared, incubated with primary anti-
bodies (HC-20 antibody for ER, Santa Cruz Biotechnology;
PELP1 antibody, Bethyl Laboratories, Montgomery, TX,
USA) at 4°C overnight. Immunocomplexes were recoveredusing protein G, washed six times in extraction buffer and
resolved by SDS-PAGE, as specified above.Statistical analysis
Statistical analysis was performed using Student’s t-test for
the qRT-PCR experiments, cycle analyses, and prolifera-
tion, apoptosis and transcription assays.Results
C-X-C chemokine receptors as potential molecular markers
associated with resistance to aromatase inhibitors
Global gene expression and Ki67 data were available
from paired baseline and 2-week posttreatment core-cut
tumour biopsies obtained from 69 postmenopausal women
with stages I to IIIB ER+ early BC who received single-
agent neoadjuvant anastrozole. These data have been
reported in detail elsewhere [12]. In BC, immunohis-
tochemical assessment of Ki67 has been validated as a
dynamic biomarker of endocrine treatment efficacy in
samples taken before, during and after neoadjuvant
endocrine therapy [17]. To identify clinically relevant
molecular markers associated with resistance to AIs that
may be assessed in our in vitro models, we identified the
intersection between genes that were significantly
upregulated in MCF7 cells adapted to LTED [11] and
genes predictive of a poor change in Ki67 in the clinical
samples. Using P <0.01 for clinical data and P <0.001 as
the levels of significance for cell line data, 32 genes were
identified as present in both data sets. Most notably,
genes associated with inflammation and immunity, such
as CXCRs, were evident (Table 1 and Additional file 1:
Figure S1). This was of particular interest because previ-
ously we had shown by molecular profiling of AI-treated
postmenopausal breast tumours that pretreatment ex-
pression of an inflammatory signature correlated with
resistance to therapy [12]. Analysis of changes in gene
expression in LTED cells versus the wt-MCF7 cells
showed that CXCR4 was upregulated 1.5-fold (P = 0.0005)
and CXCR7, the suggested coreceptor for CXCR4 [18],
was the top upregulated gene, with an increase of 17.9-fold
(P = 3.6 × 10−6) compared to wt-MCF7 cells. Crosstalk
between CXCR4 and CXCR7 is well established [19] and
is known to regulate more than 170 common genes (data
not shown). Therefore, we sought to determine their
expression and that of their associated ligands (CXCL11
and CXCL12) in a panel of LTED cells. CXCR4 and
CXCR7 were significantly increased in all LTED cell
line derivatives compared to their associated parental
cells. CXCL11 expression was restricted to wt-MCF7,
wt-SUM44 and wt-HCC1428 cells and was significantly
reduced in their LTED derivatives. CXCL12 was unde-
tected in wt-SUM44 and SUM44-LTED cells, and it was
lost in all other LTED cells except MCF7-LTED (Figure 2).
Table 1 Identification of 32 genes associated with poor response to aromatase inhibitor therapy
Gene Name In vitro Clinical
Fold change P-value Correlation coefficient P-value
ACTR2 ARP2 actin-related 2 homolog (yeast) 1.82 2.74E-05 −0.378 9.68E-04
AP1B1 Adaptor-related protein complex 1, β1 subunit 1.67 6.25E-04 −0.398 4.96E-04
ARID3A AT rich interactive domain 3A (BRIGHT-like) 1.60 1.36E-04 −0.352 2.25E-03
CCM2 Cerebral cavernous malformation 2 1.94 5.07E-05 −0.36 1.72E-03
CXCR4 Chemokine (C-X-C motif) receptor 4 1.51 5.05E-04 −0.302 9.26E-03
DTX2 Deltex homolog 2 (Drosophila) 2.24 8.19E-04 −0.338 3.41E-03
EML4 Echinoderm microtubule–associated protein–like 4 2.50 1.60E-06 −0.336 3.59E-03
FAM38A Family with sequence similarity 38, member A 3.59 5.02E-05 −0.338 3.42E-03
FBXL10 Lysine (K)-specific demethylase 2B 3.12 8.80E-06 −0.3 9.70E-03
IFNAR2 Interferon (α, β and ω) receptor 2 1.50 2.36E-04 −0.313 6.79E-03
IFNGR1 Interferon γ receptor 1 1.85 1.02E-04 −0.356 1.99E-03
IGF2R Insulin-like growth factor 2 receptor 2.93 1.20E-06 −0.319 5.84E-03
KIAA0513 KIAA0513 4.21 2.42E-04 −0.379 9.43E-04
LILRB1 Leukocyte immunoglobulin-like receptor, subfamily B, member 1 1.61 1.77E-04 −0.389 6.80E-04
LILRB3 Leukocyte immunoglobulin-like receptor, subfamily B, member 3 2.06 2.50E-06 −0.366 1.42E-03
MAP3K7 Mitogen-activated protein kinase 7 1.97 7.90E-06 −0.334 3.84E-03
MFHAS1 Malignant fibrous histiocytoma-amplified sequence 1 2.11 1.79E-05 −0.299 9.76E-03
MGAT1 Mannosyl glycoprotein acetylglucosaminyltransferase 1.70 1.33E-04 −0.313 6.78E-03
MICAL1 Microtubule-associated monooxygenase, calponin/LIM domain 2.43 7.00E-07 −0.385 7.65E-04
NPC2 Niemann-Pick disease, type C2 2.37 3.09E-05 −0.421 2.12E-04
PHACTR2 Phosphatase and actin regulator 2 3.20 1.22E-05 −0.35 2.39E-03
PLEKHF1 Pleckstrin homology domain containing, family F, member 1 2.13 3.51E-05 −0.369 1.31E-03
RGS19 Regular of G-protein signaling 19 1.52 7.14E-04 −0.474 2.54E-05
SLC15A4 Solute carrier family 15, member 4 1.54 9.13E-05 −0.307 7.91E-03
ST8SIA4 ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 4 2.45 2.74E-04 −0.32 5.64E-03
TNRC6B Trinucleotide repeat containing 6B 2.13 1.90E-04 −0.3 9.74E-03
TTYH3 Tweety homolog 3 (Drosophila) 2.72 4.65E-04 −0.408 3.42E-04
WDFY1 WD repeat and FYVE domain containing 1 2.27 3.00E-06 −0.349 2.40E-03
XPO6 Exportin 6 1.80 4.64E-04 −0.312 6.99E-03
YWHAH Tyrosine/tryptophan monooxygenase activation protein 1.44 4.83E-04 −0.365 1.50E-03
ZBED4 Zinc finger, BED-type containing 4 1.59 5.93E-05 −0.337 3.48E-03
ZCCHC11 Zinc finger, CCHC domain containing 11 1.36 4.75E-04 −0.433 1.36E-04
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proliferation
To determine the relevance of CXCR4 and CXCR7 on cell
proliferation, we selected LTED cell lines that retained
expression of ER (Additional file 2: Figure S2) and at least
one of the ligands for CXCR4 and CXCR7 (Figure 2),
along with their parental lines. siCXCR4 showed a min-
imal, nonspecific antiproliferative effect in the four cell
lines tested with or without E2 (Figure 3A). In contrast,
compared to sicontrol, siCXCR7 significantly inhibited
proliferation of MCF7-LTED cells by 45% (P <0.001) in
the absence of E2 and by 32% (P <0.001) in the presenceof E2. Depletion of CXCR7 in wt-MCF7 had a statistically
significant but quantitatively modest effect, suppressing
proliferation by 17% in the absence of E2 (P <0.05) and no
significant effect in the presence of E2 (Figure 3B). In
contrast, suppression of CXCR7 showed no selective in-
hibition of proliferation in wt-SUM44 and SUM44-LTED.
As CXCR4 and CXCR7 show a high degree of crosstalk,
we assessed whether the combination of siCXCR4 and
siCXCR7 would induce a greater antiproliferative effect
compared with siCXCR7 alone. No significant effect of the
combination was noted in any of the cell lines tested, with
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Figure 2 CXCR4, CXCR7, CXCL11 and CXCL12 expression in five
oestrogen receptor–positive human breast cancer cell lines
adapted to long-term oestrogen deprivation. Expression of CXCR4
(A), CXCR7 (B), CXCL11 (C) and CXCL12 (D) in wild-type (WT) and their
corresponding long-term oestrogen-deprived (LTED) cell lines. CXCR,
C-X-C chemokine receptor; CXCL, C-X-C chemokine ligand. Bars represent ±
standard error of the mean (SEM) *P<0.05 ** P<0.01, ***P<0.001
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statistically significance (Additional file 3: Figure S3). These
data suggest that the antiproliferative effect of siCXCR7 in
MCF7-LTED cells maybe context-specific.
Relationship between CXCR4 and CXCR7 expression and
long-term outcome in oestrogen receptor–positive breast
cancer patients
Using public data from untreated patients with ER+ BC
with 12 years of follow-up, high levels of CXCR7 were
found to be associated with poor RFS. In contrast, CXCR4
was not significantly associated with RFS (Figure 3C).
Using gene expression data from patients treated with
tamoxifen [13], CXCR7 was found to be associated with
a significant reduction in time to relapse (0 to 12 years),
whereas CXCR4 was not (Figure 3C). Assessment of CXCR4
expression over the course of 0 to 5 years showed a sig-
nificant association with poor RFS during this time frame
(Additional file 4: Figure S4A), whereas the RFS curves
closed after 5 years, indicating little association with late
recurrence after treatment had ceased (Figure 3C).
To model this clinical observation in vitro, wt-MCF7
cells were deprived of E2 for 1 week (short-term oestrogen
deprivation, STED) or for 20 weeks (LTED). Alterations in
CXCR4 and CXCR7 expression were evaluated by qRT-
PCR. After 1 week (STED), both CXCR4 and CXCR7
increased significantly (6-fold and 13-fold, respectively)
compared with the parental cells. However, after 20 weeks
of deprivation, CXCR4 was significantly reduced in com-
parison with the STED (1.7-fold decreased, P <0.001).
In contrast, CXCR7 was significantly increased (4-fold,
P = 0.01) (Additional file 4: Figure S4B).
In summary, although CXCR4 was minimally upregu-
lated in the LTED cells, a model of late relapse, it may
no longer play a significant role in proliferation, as indi-
cated by our siRNA knockdown studies. In contrast,
CXCR7 was highly expressed and had specific targetable
proliferative activity in this setting.
On the basis of these clinical and in vitro data, we fo-
cused our attention on the role of CXCR7 in late relapse.
Characterisation of CXCR7 in long-term
oestrogen-deprived MCF7 versus wild-type MCF7
Using deconvoluted siRNAs targeting CXCR7, we con-
firmed the antiproliferative effect of CXCR7 depletion
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Figure 3 (See legend on next page.)
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Figure 3 Analysis of CXCR4 and CXCR7 in cell lines and clinical data on association with recurrence of oestrogen receptor–positive
breast cancer. wt-MCF7, MCF7-LTED, wt-SUM44 and SUM44-LTED cells were transfected with siCXCR4 (A) or siCXCR7 (B) versus sicontrol ± exogenous
oestradiol (E2) (1 nM). Cells were cultured for 6 days. Cell survival was measured using CellTiter-Glo. The data are expressed as fold changes relative to
sicontrol. Each treatment was carried out with eight replicates. The data shown are representative of a minimum of five independent experiments.
Bars represent ± standard error of the mean (SEM). *P <0.05, **P <0.01, ***P <0.001. (C) Kaplan-Meier analysis of the influence of CXCR4 and CXCR7 on
relapse-free survival (RFS) in patients with oestrogen receptor–positive (ER+) breast cancer (BC), who were either treatment-naïve or treated with tamoxifen,
whose data were derived from publicly available clinical BC data sets collected over 12 years [13]. Data were stratified by the highest quartile versus the
rest. CXCR, Chemokine C-X-C receptor; DCC, Dextran-coated charcoal; LTED, Long-term oestrogen deprivation; si, Small interfering; wt, Wild type.
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antibodies for immunoblotting [20]; therefore, we perfor-
med immunohistochemical and FACS analysis to compare
the protein expression of CXCR7 between wt-MCF7 and
MCF7-LTED, having first confirmed antibody specificity
using confocal microscopy, which showed loss of staining
after siCXCR7. There was an increase of CXCR7 protein
levels in MCF7-LTED compared to wt-MCF7 cells. MDA-
MB-231 cells, which do not express CXCR7, were used
as a negative control for both MCF7-LTED and wt-
MCF7 cells by immunohistochemical and FACS analysis
(Additional file 6: Figure S6).
CXCR7 depletion does not enhance apoptosis in vitro
CXCR7 can signal through β-arrestin [21]. β-arrestin has
been linked to prosurvival signalling by enhancing BCL2
expression by promoting acetylation of histone H4 at
the BCL2 promoter [22]. Therefore, we hypothesised
that increased CXCR7 might lead to increased expres-
sion of BCL2 via β-arrestin. siCXCR7 significantly re-
duced BCL2 transcript levels in MCF7-LTED, but not in
SUM44-LTED cells. No effect upon BCL2 protein ex-
pression was evident in either cell line model. Further-
more, depletion of CXCR7 did not affect PARP cleavage
(Figures 4A and 4B), and no increase in cell death was
evident using live/dead viability assays. Similarly, no
increase was found in the sub-G1 fraction in response to
siCXCR7 (Additional file 7: Figure S7). siCXCR7 had no
effect on expression of β-arrestin 1 or 2 in either cell
line. Most notably, no significant alteration in the expres-
sion of β-arrestin 1 was evident between the cell lines,
although MCF7-LTED cells showed loss of expression of
β-arrestin 2. Furthermore, both β-arrestins 1 and 2 were
suppressed by addition of exogenous E2 in the MCF7-
LTED and its wild type, although this was not the case
in the wt-SUM44 and SUM44-LTED cells (Figure 4A).
Therefore, these data suggest that crosstalk between
CXCR7 and β-arrestin did not impede apoptosis in the
LTED cell line.
CXCR7 depletion blocks cell cycle progression and
G1/S transition
We performed flow cytometry to assess whether the
antiproliferative effect of siCXCR7 in MCF7-LTED andSUM-44 cells results from cell cycle arrest in response
to siCXCR7. siCXCR7 caused a significant decrease in
S-phase without and with E2 (40% decrease without E2
(p = 0.0007) and 42% decrease with E2 (P = 0.006)), and
a concomitant increase in G1-phase, compared to sicontrol
in MCF7-LTED cells. In contrast, siCXCR7 caused a min-
imal decrease in the number of cells in S-phase in
the SUM44-LTED cells (15% (P = 0.01) in DCC and 12%
(P = 0.03) in E2) (Figure 4C). This is in keeping with the
limited antiproliferative effect noted previously (Figure 3A).
Furthermore, siCXCR7 had negligible effects on expression
of cell cycle regulatory proteins in either wt-SUM44 or
SUM44-LTED cells. In contrast, siCXCR7 decreased ex-
pression of cell cycle regulatory proteins, predominantly in
the MCF7-LTED cells in the absence of E2 but also in the
presence of E2. No suppression of these already low levels
of cell cycle proteins in response to siCXCR7 was observed
in wt-MCF7 cells in the absence of E2, and only a minimal
effect was evident in the presence of E2 (Figure 4D).
CXCR7 knockdown affects oestrogen receptor–mediated
transactivation in MCF7-LTED cells
MCF7-LTED cells upregulate ER expression and are
dependent on ER/ERE-driven transcription for prolifera-
tion [5]. siCXCR7 had no effect on ER-mediated transcrip-
tion in the wt-MCF7 cells in the presence or absence of
E2. However, depletion of CXCR7 resulted in a 40%
decrease (P <0.001) in the MCF7-LTED cells compared to
sicontrol in the absence of E2. No significant changes
were observed in MCF7-LTED cells in the presence of E2
(Figure 5A). Similarly, siCXCR7 had no effect on the
expression of TFF1, an endogenous oestrogen-regulated
gene in wt-MCF7 cells, but resulted in a 30% reduction
(P <0.01) in the MCF7-LTED cells in the absence of E2.
siCXCR7 knockdown did not affect TFF1 expression in
MCF7-LTED cells in the presence of E2 (Figure 5B).
Depletion of CXCR7 does not affect downstream
pathways associated with oestrogen receptor
phosphorylation
Studies have suggested that aberrant kinase activity can
lead to the ligand-independent phosphorylation of ER at
serine 167 and serine 118. siCXCR7 in the presence or
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Figure 4 (See legend on next page.)
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Figure 4 Depletion of CXCR7 causes cell cycle arrest, but not apoptosis. wt-MCF7, MCF7-LTED, wt-SUM44 and SUM44-LTED cells were
transfected with sicontrol or siCXCR7 ± oestradiol (E2) for 72-hours. (A) Whole-cell extracts were immunoblotted and assessed for changes in expression
of BCL2, cleaved poly(ADP-ribose) polymerase (PARP) and β-arrestins 1 and 2. (B) Changes in BCL2 were assessed by quantitative RT-PCR. Data are
expressed relative to dextran-coated charcoal (DCC)–treated sicontrol. (C) Assessment of alteration in S- and G1-phase accumulation as a result of
CXCR7 depletion. Data are expressed as mean ± SEM. *P <0.05, **P <0.01, ***P <0.001. (D) Immunoblot analysis of cell cycle markers in response to
CXCR7 depletion. Data shown are representative of a minimum of three independent experiments. CXCR, C-X-C chemokine receptor; LTED, Long-term
oestrogen deprivation; si, Small interfering; wt, Wild type.
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phosphorylated kinases associated with ER function. Fur-
thermore, no significant changes in the phosphorylation
of ER were evident (Figure 5C).
CXCR7 depletion impeded the interaction between
oestrogen receptor and coactivator PELP1
ER function is dependent on the recruitment of coactiva-
tors. Recent studies have suggested that CDK4 is required
for phosphorylation of PELP1, allowing interaction with
ER [23]. We previously showed that siCXCR7 signifi-
cantly reduced expression of CDK4 in MCF7-LTED cells
(Figure 4D); therefore, we postulated that siCXCR7 may
impede the interaction between ER and PELP1, leading to
a reduction in ER-mediated transcription and concomitant
decrease in proliferation. siCXCR7 caused a significant
reduction in the association between PELP1 and ER in
LTED cells compared to sicontrol. Furthermore siESR1
and siPELP1 produced similar results (Figure 5D).
CCX733 specifically inhibits proliferation of MCF7-LTED
cells, but not wt-MCF7 cells
To address whether CXCR7 could be a clinically relevant
drug target, we assessed the sensitivity of MCF7-LTED
versus wt-MCF7 cells to escalating concentrations of
CCX733, a specific antagonist of the activity of CXCR7,
but not of CXCR4 activity [24]. CCX733 had no effect
on the proliferation of wt-MCF7 cells with or without
E2 (Figure 6A), but caused a dose-dependent decrease in
proliferation of MCF7-LTED cells, which was enhanced
in the absence of E2 (Figure 6B), consistent with our
previous observation using siCXCR7 (Figure 3B). As a
negative control, we assessed the effect of CCX704, an
analogue with no binding affinity for CXCR7. CCX704
had no antiproliferative effect in either cell line, as ex-
pected (Figure 6C). To further address the combination
effects, we combined CXCR7 depletion with fulvestrant,
which showed a 35% enhancement in the antiprolifera-
tive effect of the combination compared with fulvestrant
alone (Additional file 8: Figure S8).
Discussion
To identify genes associated with resistance to AI therapy
that could be manipulated in our model system, we identi-
fied the overlap between genes whose expression changesin MCF7 cells adapted to LTED and genes whose expres-
sion relates to the antiproliferative response of ER+ tu-
mours from patients treated with neoadjuvant anastrazole.
Using this strategy, we removed any contribution from the
tumour stroma, thus allowing identification of pathways
that were solely tumour-associated. The predominant
genes linked with poor response to anastrazole therapy
were those associated with inflammation and immunity,
such as CXCRs. In vitro analysis of a panel of cell lines
modelling adaptation to LTED showed that both CXCR4
and CXCR7 were overexpressed compared to the parental
cell lines. CXCR4, CXCR7 and their shared ligand CXCL12
are thought to affect several major signalling pathways
involved in cell survival, proliferation and metastasis
[10]. High expression of CXCR4 has been associated
with invasion and migration of tumour cells in patients
with BC [25,26], a role confirmed both in vivo and
in vitro [27,29].
To confirm the clinical relevance of CXCR4 and
CXCR7, we assessed the effect of expression in publicly
available clinical data sets, restricting significance only
to patients with ER+ disease who had not received adju-
vant endocrine treatment. Notably, CXCR7 expression,
but not CXCR4 expression, was prognostic for poor RFS.
Furthermore, interrogation of global gene expression
data from a cohort of ER+ patients who had received
adjuvant tamoxifen therapy showed similarly that CXCR7,
but not CXCR4, was associated with poor RFS. Further
analysis suggested that CXCR4 was in fact associated with
early (0 to 5 years) but not late relapse.
As the large majority of patients at relapse continue to
express the ER, we postulated that the role of CXCR7 in
resistance to AI therapy was associated with continued
expression of ER. However, SUM44-LTED cells which
continued to express ER showed no specific response to
CXCR7 depletion. Furthermore HCC1428-LTED lost ex-
pression of both CXCL11 and CXCL12, a feature associated
with chemotactic response to ligand gradients and not
associated with proliferation [30]. In contrast, MCF7-LTED
cells were significantly and specifically inhibited by deple-
tion of CXCR7 either using a siRNA or by chemical inter-
vention with CCX733. This suggests that the increase in
CXCR7 expression and activity may be constrained by the
genetic background of MCF7 cells, which remain the most
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Figure 5 CXCR7 is required for the interaction between oestrogen receptor and PELP1. wt-MCF7 and MCF7-LTED cells were transfected
with sicontrol or siCXCR7. (A) Oestrogen receptor/oestrogen response element (ER/ERE) transactivation was monitored with an ERE-linked luciferase
reporter and pCH110 (β-galactosidase control) and expressed relative to dextran-coated charcoal (DCC) control. (B) Expression of TFF1 was assessed
by quantitative RT-PCR, as previously described. Error bars represent ± SEM. *P <0.05, **P <0.01. (C) Immunoblot analysis of kinases associated with
phosphorylation of ER in response to CXCR7 depletion. (D) MCF7-LTED cells were left untreated or transfected with sicontrol, siCXCR7, siPELP1 or siESR1,
immunoprecipitated for PELP1; and immunoblotted for ER or vice versa. The data shown are representative of three independent experiments. CXCR,
Chemokine C-X-C receptor; E2, Oestradiol; IP, Immunoprecipitation; JNK, c-Jun N-terminal kinase; LTED, Long-term oestrogen deprivation; PELP,
Proline-, glutamic acid– and leucine-rich protein 1; si, Small interfering; wt, Wild type.









































































Figure 6 Treatment of wt-MCF7 and MCF7-LTED cells with escalating concentrations of CXCR7 inhibitor CCX733 with or without
exogenous oestradiol. wt-MCF7 cells (A) and MCF7-LTED cells (B) were treated with escalating concentrations of CCX733 for 6 days. Cell survival
was measured using CellTiter-Glo. The data are expressed as fold changes relative to vehicle-treated control (0). (C) MCF7-LTED and wt-MCF7 cells
were treated with CCX704 as a negative control. CXCR, Chemokine C-X-C receptor; DCC, Dextran-coated charcoal; E2, oestradiol; LTED, Long-term
oestrogen deprivation; wt, Wild type. *P<0.05 ** P<0.01, ***P<0.001.
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http://breast-cancer-research.com/content/16/6/447Contrary to classical chemokine receptors, CXCR7 does
not respond to ligand binding by mobilising intracellular
calcium via G protein–coupled receptors, and recent stud-
ies have proposed that CXCR7 may be capable of asso-
ciating and signalling via β-arrestin–mediated pathways
[21]. β-arrestins are multifunctional adaptor proteins thatfacilitate receptor trafficking [31] and can act as bona fide
signal transducers [32]. More recently, it has been shown
that β-arrestins can translocate to the nucleus and regu-
late transcriptional events [33], including expression of
the antiapoptotic protein BCL2 [34]. However, in our
studies, although there was a noticeable decrease in BCL2
Ribas et al. Breast Cancer Research 2014, 16:447 Page 13 of 15
http://breast-cancer-research.com/content/16/6/447mRNA (discussed below), siCXCR7 had no effect on
BCL2 protein expression or apoptosis and had no effect
on β-arrestin expression.
Strikingly, whilst wt-MCF7 and MCF7-LTED cells
expressed similar levels of β-arrestin 1, MCF7-LTED cells
showed loss of β-arrestin 2. This could have several effects
on the ability of the MCF7-LTED cells to proliferate in the
absence of E2. First, loss of β-arrestins leads to chromo-
somal instability, a feature often observed in BC [35,36],
and may provide the LTED cells with a plastic genetic
background. Second, a previous study has shown that β-
arrestin 2 acts as a corepressor of androgen receptor (AR)
suppressing AR-mediated transcription. Given that loss of
β-arrestin 2 has been shown to promote AR transcrip-
tional activity, loss of β-arrestin 2 in MCF7-LTED cells
might also enhance ER-mediated transcription in the
absence of exogenous E2 [37].
Our data suggest that CXCR7 most likely played a role
in cell cycle progression in the MCF7-LTED cell line.
This was confirmed by the significant reduction in expres-
sion of cell cycle proteins cyclin D1, CDK4 and phosphor-
ylated Rb in MCF7-LTED cells, but not in wt-MCF7 cells,
in response CXCR7 depletion. Consistent with our data,
in recent studies of metastatic prostate cancer cell lines,
researchers found that siCXCR7 caused multiple antitu-
mour effects, including a decrease in proliferation and cell
cycle arrest in the G1 phase, as well as expression of pro-
teins involved in G1/S phase progression [38].
As the MCF7-LTED cells are dependent on ER-mediated
transcription for proliferation [5,39], we hypothesised that
CXCR7, via its interaction with the signal transduction
kinases, could lead to ligand-independent activation of ER.
For instance, previous studies have shown that CXCL12/
CXCR4 can lead to activation of downstream signal-
ling pathways implicated in the development of resist-
ance to endocrine therapy, such as mitogen-activated
protein kinase family members as well as PI3K/Akt
cascades [40,43].
siCXCR7 significantly reduced ER-mediated transacti-
vation as measured by an ERE luciferase-linked reporter
construct in MCF7-LTED cells, but not in wt-MCF7 cells,
in the absence of E2. However, no decrease in expres-
sion of kinases associated with ligand-independent or
ligand-dependent ER phosphorylation, such p38, pERK1/2,
pAKT, pJNK or pCDK7 [44,45] was evident in response to
CXCR7 depletion. Furthermore, the main phosphorylation
sites on ER, serine 118 and serine 167, also were not
significantly altered.
ER-mediated transcription is also dependent on the
recruitment of nuclear coactivators, which are similarly
controlled by phosphorylation [46]. One of the major
coactivators associated with endocrine resistance is PELP1/
MNAR [47]. Previous studies have shown that CDK4-
mediated phosphorylation of PELP1 is critical for itsoncogenic function and its association with ER [23]. We
hypothesised that CXCR7, via crosstalk with PELP1, was
leading to enhanced ER-mediated transcription in the
absence of E2 in the MCF7-LTED cell line. As expected,
siCXCR7 decreased the association between ER and
PELP1 in MCF7-LTED cells and was associated with a
concomitant decrease in expression of the endogenous
E2-regulated gene TFF1. Of interest, BCL2 is also a clas-
sically ER-ERE–mediated gene. We previously noted that
mRNA levels were suppressed by siCXCR7, providing
further support for this mechanism.
Conclusions
By using an in vitro model of endocrine resistance, we have
provided evidence of novel crosstalk between ER and
CXCR7 that leads to ligand-independent, ER-mediated
transactivation via the ER coactivator PELP1. Furthermore,
the therapeutic potential of directly targeting this unique
crosstalk was highlighted by the antiproliferative effect of
the CXCR7 antagonist CCX733. CXCR7 expression asso-
ciates clinically with poor overall survival in patients with
ER+ BC. Overall, these data indicate that CXCR7 may
be both a potential biomarker and a therapeutic target
in endocrine-resistant BC that warrants further clinical
investigation.
Additional files
Additional file 1: Figure S1. Identification of genes associated with
resistance to aromatase inhibitor therapy. Intersection of genes from
patients treated with neoadjuvant anastrazole that predict for a poor
change in Ki67 (P <0.01) with genes associated with adaptation of wt-
MCF7 cells to LTED (P <0.001).
Additional file 2: Figure S2. Oestrogen receptor expression analysis in
a panel of human breast cancer cell lines and their LTED derivatives.
MCF7-LTED, SUM44-LTED and HCC1428-LTED cells keep expression of ER,
but T47D-LTED and ZR75-LTED loose ER expression.
Additional file 3: Figure S3. Depletion of CXCR4 and CXCR7 causes
no additional antiproliferative effect versus siCXCR7 alone. wt-MCF7,
MCF7-LTED, wt-SUM44 and SUM44-LTED cells were transfected with
siCXCR7 alone or with a combination of siCXCR4 and siCXCR7.
Additional file 4: Figure S4. Association of CXCR4 and CXCR7 with
recurrence in oestrogen receptor–positive breast cancer treated with
endocrine therapy and in vitro modelling of short (STED) or late
oestrogen deprivation (LTED). (A) Kaplan-Meier analysis of CXCR4 and
CXCR7 over 0-5years in ER+ BC patients from a series of 840 patients
treated with tamoxifen. Data was stratified by the highest quartile versus
the rest. (B) Expression of CXCR4 and CXCR7 in wt-MCF7 cells and short
(STED) or long term oestrogen deprivation (LTED).
Additional file 5: Figure S5. Deconvolution of CXCR7 siRNA
SMARTpool. MCF7-LTED cells were transfected with each siRNA within
the CXCR7 SMARTpool individual. All except oligo 4 resulted in a
significant decrease in proliferation.
Additional file 6: Figure S6. Protein expression of CXCR7. (A)
MCF7-LTED cells were transfected with sicontrol or siCXCR7. After 48-hours
monolayers were stained for CXCR7 and visualised by confocal microscopy.
(B) MCF7-LTED, wt-MCF7 and MDA MB 231 (negative control) cells were
formalin fixed and paraffin embedded. Sections were stained for expression
of CXCR7. (C) Wt-MCF7, MCF7-LTED and MDA MB 261 cells were stained for
CXCR7 and expression visualised by FACS.
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http://breast-cancer-research.com/content/16/6/447Additional file 7: Figure S7. Assessment of apoptosis. (A) MCF7-LTED
cells were transfected with sicontrol or siCXCR7. After 24-hours cells were
treated ± E2. 24-hours cells later monolayers were stained with PI and the
fraction of cells in sub-G1 determined by FACS. Data is expressed as
percentage relative to sicontrol. (B) Cells were seeded into 24-well plates,
transfected with the siRNAs indicated and 48-hours later assessed for
apoptosis using a live/dead assay (Roche Life Science). Data are expressed
as fold changes relative to sicontrol.
Additional file 8: Figure S8. Effect of the combination of siCXCR7 with
fulvestrant (ICI 182,780) on proliferation of MCF7-LTED. MCF7-LTED cells
were transfected with sicontrol or siCXCR7 and followed by treatment
with 1 nM of fulvestrant in the presence of oestrogen.
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